MedPath

MEN-10755 in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2
Completed
Conditions
Prostate Cancer
Registration Number
NCT00027781
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of MEN-10755 in treating patients who have progressive prostate cancer that has not responded to hormone therapy.

Detailed Description

OBJECTIVES:

* Assess the activity of MEN-10755 in patients with progressive hormone-refractory adenocarcinoma of the prostate.

* Determine the rate and duration of objective PSA response in patients treated with this drug.

* Determine the clinical response rate in patients with measurable disease treated with this drug.

* Determine the acute side effects of this drug in these patients.

OUTLINE: This is a multicenter study.

Beginning within 2 weeks after the last PSA measurement, patients receive MEN-10755 IV over 30 minutes on day 1. Treatment repeats every 3 weeks for at least 4 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete or partial response continue to receive additional courses. Patients who achieve stable disease may receive more than 4 courses at the discretion of the investigator.

Patients are followed every 6 weeks until disease progression or initiation of a new therapy.

PROJECTED ACCRUAL: A total of 18-32 patients will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
37
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (10)

Rabin Medical Center - Beilinson Campus

🇮🇱

Petah-Tikva, Israel

Centre Jean Perrin

🇫🇷

Clermont-Ferrand, France

Hospital Universitario 12 de Octubre

🇪🇸

Madrid, Spain

Centre de Lutte Contre le Cancer, Georges-Francois Leclerc

🇫🇷

Dijon, France

CHU de la Timone

🇫🇷

Marseille, France

CHU Pitie-Salpetriere

🇫🇷

Paris, France

Inselspital, Bern

🇨🇭

Bern, Switzerland

Universitaets-Krankenhaus Eppendorf

🇩🇪

Hamburg, Germany

Universitair Ziekenhuis Antwerpen

🇧🇪

Edegem, Belgium

Institut Bergonie

🇫🇷

Bordeaux, France

© Copyright 2025. All Rights Reserved by MedPath